MedTrace Logo

Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C

NCT01274208 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2014-11-19

No results posted yet for this study

Summary

Study objectives:

* Investigate the anti-HCV response in patients with Gaucher disease(GD)
* Define the potential role of high levels of Glucocerebroside in the immune system

Study hypothesis:

High levels of Glucocerebroside can be used as a tool in the antiviral treatment of hepatitis C by potentiating the immune response of natural killer T cells and dendritic cells

Conditions

  • Gaucher Disease
  • Hepatitis C

Sponsors & Collaborators

  • Shaare Zedek Medical Center

    lead OTHER

Principal Investigators

  • Bernardo Melamud, Dr. · Gaucher Clinic , Shaare zedek Hospital

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2016-03-31
Completion
2016-04-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01274208 on ClinicalTrials.gov